Fibroblastic reticular cell-derived exosomes are a promising therapeutic approach for septic acute kidney injury
Quick Facts
- Publication title: Fibroblastic reticular cell-derived exosomes are a promising therapeutic approach for septic acute kidney injury
- Journal: Kidney Int
- Year: 2024
- DOI: 10.1016/j.kint.2023.12.007
- PMID/PMCID: 38163633
Research overview
To dissect the mechanism underlying the protective role of Exos in S-AKI, we examined the proteins within Exos by mass spectrometry and found that CD5L was the most upregulated protein in FRC-Exos compared to macrophage-derived Exos. Thus, strategies to modify FRC-Exos could be a new avenue in developing therapeutics against kidney injury.
Key findings
Sepsis-induced acute kidney injury (S-AKI) is highly lethal, and effective drugs for treatment are scarce.
Previously, we reported the robust therapeutic efficacy of fibroblastic reticular cells (FRCs) in sepsis.
Here, we demonstrate the ability of FRC-derived exosomes (FRC-Exos) to improve C57BL/6 mouse kidney function following cecal ligation and puncture-induced sepsis.
In vivo imaging confirmed that FRC-Exos homed to injured kidneys.
Echo Biotech Role
Echo Biotech contributed targeting-peptide/surface modification; the study also used or cited ExoBrooch™.
Related platforms: Echosome®, Research Reagents & Tools
Related services and capabilities: Targeting Peptide / Surface Modification, Research Reagent / Product Supply
Related products or reagents: ExoBrooch™ Targeting Peptide/Lipid Anchor Kit
References
Original publication: Fibroblastic reticular cell-derived exosomes are a promising therapeutic approach for septic acute kidney injury Kidney Int. 2024. DOI: 10.1016/j.kint.2023.12.007. PMID/PMCID: 38163633.